4th Quarter 2024 Results February 27, 2025 Parth Mehrotra, CEO David Mountcastle, CFO Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to: 2025 financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of whic ...

分组1 - Privia Health reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share, representing an earnings surprise of -50% [1] - The company posted revenues of $460.9 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 10.37%, compared to year-ago revenues of $440.83 million [2] - Privia Health shares have increased by approximately 23.1% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $455.78 million, and $0.27 on revenues of $1.88 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical Info Systems industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8]

Full-Year Performance Exhibit 99.1 | | | | For the Years Ended December 31, | | | | --- | --- | --- | --- | --- | --- | | ($ in millions, except per share amounts) | | 2024 | | 2023 | * Change (%) | | Total revenue | $ | 1,736.4 | $ | 1,657.7 | 4.7 % | | Gross profit | $ | 397.7 | $ | 353.8 | 12.4 % | | Operating income | $ | 17.0 | $ | 20.6 | (17.8)% | | a Net income | $ | 14.4 | $ | 23.1 | (37.7)% | | b Non-GAAP adjusted net income | $ | 97.6 | $ | 81.5 | 19.8 % | | Net income per share | $ | 0.11 | $ | 0 ...

Core Insights - Privia Health Group, Inc. reported strong financial and operational results for the fourth quarter and full year ended December 31, 2024, exceeding the high end of its guidance ranges for 2024 [1] Full-Year Performance - Total revenue increased to $1,736.4 million in 2024, up 4.7% from $1,657.7 million in 2023 [2] - Gross profit rose to $397.7 million, reflecting a 12.4% increase from $353.8 million in 2023 [2] - Operating income decreased to $17.0 million, down 17.8% from $20.6 million in 2023 [2] - Net income fell to $14.4 million, a decline of 37.7% from $23.1 million in 2023 [2] - Non-GAAP adjusted net income increased to $97.6 million, up 19.8% from $81.5 million in 2023 [2] - Net income per share decreased to $0.11, down 42.1% from $0.19 in 2023 [2] - Non-GAAP adjusted net income per share increased to $0.78, up 21.9% from $0.64 in 2023 [2] Key Operating Metrics - Implemented Providers increased by 11.2% to 4,789 from 4,305 at year-end 2023 [5][7] - Attributed Lives grew by 12.1% to 1,256,000 from 1,120,000 in 2023 [7] - Practice Collections reached $2,968.0 million, a 4.5% increase from $2,839.0 million in 2023 [7] - Care Margin improved to $403.9 million, up 12.4% from $359.2 million in 2023 [7] - Adjusted EBITDA grew by 25.2% to $90.5 million from $72.2 million in 2023 [6][7] Fourth Quarter Performance - Total revenue for Q4 2024 was $460.9 million, a 4.6% increase from $440.8 million in Q4 2023 [9] - Gross profit for Q4 2024 was $106.1 million, up 18.0% from $90.0 million in Q4 2023 [9] - Operating income surged to $5.2 million, a 269.6% increase from $1.4 million in Q4 2023 [9] - Net income for Q4 2024 was $4.4 million, a 55.0% increase from $2.8 million in Q4 2023 [9] - Non-GAAP adjusted net income for Q4 2024 was $26.5 million, up 30.5% from $20.3 million in Q4 2023 [9] Capital Resources and Cash Flow - The cash balance at year-end 2024 was $491.1 million, a 26.1% increase from $389.5 million at year-end 2023 [12] - Net cash provided by operating activities for 2024 was $109.3 million, a 35.3% increase from $80.8 million in 2023 [12] - Free cash flow for 2024 was $109.3 million, up 35.4% from $80.7 million in 2023 [12] 2025 Financial and Business Outlook - The company expects to increase Implemented Providers to between 5,200 and 5,300, representing a year-over-year growth of 8.6% to 10.7% [13] - Attributed Lives are projected to grow to between 1,300,000 and 1,400,000, a 3.5% to 11.5% increase [13] - Practice Collections are expected to reach between $3,150 million and $3,250 million, reflecting a 6.1% to 9.5% increase [13] - GAAP Revenue guidance for 2025 is set between $1,800 million and $1,900 million, indicating a 3.7% to 9.4% increase [13]

Core Insights - Wall Street analysts anticipate Privia Health (PRVA) will report quarterly earnings of $0.06 per share, reflecting a year-over-year increase of 200% [1] - Expected revenues for the quarter are $417.6 million, which represents a decline of 5.3% compared to the same quarter last year [1] - The consensus EPS estimate has remained stable over the past 30 days, indicating a reevaluation of initial estimates by analysts [1] Earnings Estimates and Market Reactions - Changes in earnings estimates are critical for predicting investor reactions to stock performance [2] - Empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [2] Key Metrics Projections - Analysts project 'Practice Collections' to reach $719.81 million, down from $756.60 million reported in the same quarter last year [4] - The estimated 'Care Margin' is $101.70 million, an increase from $91.45 million in the previous year [4] - The consensus for 'Platform Contribution' is expected to be $48.89 million, up from $42.28 million reported in the same quarter last year [5] Stock Performance - Privia Health shares have increased by 7.2% over the past month, contrasting with a -1.8% change in the Zacks S&P 500 composite [5] - With a Zacks Rank of 3 (Hold), PRVA is expected to perform in line with the overall market in the near future [5]

Core Viewpoint - Privia Health Group, Inc. is set to announce its financial results for the fourth quarter and full-year periods ending December 31, 2024, on February 27, 2025, before market open [1]. Financial Results Announcement - The financial results press release will be publicly available by 7:00 am ET on February 27, 2025, and can be accessed on the company's Investor Relations website [2]. - A conference call will be hosted by Privia Health management at 8:00 am ET on the same day to discuss the financial results and future outlook [2][3]. Conference Call Details - The conference call can be accessed via live webcast, with an archived version available for on-demand listening shortly after the call [3]. - To participate in the live call, interested parties can dial 646-968-2525 or 888-596-4144 for international callers, using Conference ID 5704885 [3]. Company Overview - Privia Health is a technology-driven national physician enablement company that collaborates with medical groups, health plans, and health systems to enhance physician practices and patient experiences [4]. - The Privia Platform is characterized by scalable operations and cloud-based technology aimed at reducing healthcare costs and improving patient outcomes [4].

Core Insights - Definitive Healthcare Corp. (DH) and Privia Health (PRVA) are being compared for their value opportunities, with DH currently rated 2 (Buy) and PRVA rated 3 (Hold) according to the Zacks Rank [2][4] - DH has a forward P/E ratio of 12.07, significantly lower than PRVA's forward P/E of 137.64, indicating a more attractive valuation for DH [3] - DH's PEG ratio is 1.32, while PRVA's PEG ratio is 5.23, suggesting that DH is expected to grow earnings at a more favorable rate relative to its price [3] - DH has a P/B ratio of 0.70 compared to PRVA's P/B of 3.63, further supporting the argument that DH is undervalued [6] - Based on these valuation metrics, DH has earned a Value grade of A, while PRVA has a Value grade of C, indicating that DH is the superior value option at this time [6] Valuation Metrics - The forward P/E ratio for DH is 12.07, while PRVA's is 137.64, highlighting a significant difference in valuation [3] - The PEG ratio for DH is 1.32, compared to PRVA's 5.23, indicating a more favorable growth outlook for DH [3] - DH's P/B ratio stands at 0.70, while PRVA's is 3.63, suggesting that DH is trading at a lower valuation relative to its book value [6] Investment Outlook - The Zacks Rank emphasizes companies with positive earnings estimate revisions, which is a favorable indicator for DH's earnings outlook [2] - Value investors typically consider various fundamental metrics, including P/E, P/S, earnings yield, and cash flow per share, to identify undervalued stocks [5] - The analysis suggests that DH presents a better value opportunity compared to PRVA based on the current financial metrics [6]

Core Insights - Definitive Healthcare Corp. (DH) and Privia Health (PRVA) are being compared for value investment opportunities, with DH currently showing stronger potential for value investors [1][3]. Valuation Metrics - DH has a forward P/E ratio of 13.79, significantly lower than PRVA's forward P/E of 148.10, indicating that DH may be undervalued [5]. - The PEG ratio for DH is 1.51, while PRVA's PEG ratio is 5.63, suggesting that DH has a more favorable growth outlook relative to its valuation [5]. - DH's P/B ratio stands at 0.79, compared to PRVA's P/B of 3.91, further indicating that DH is more attractively priced relative to its book value [6]. Investment Grades - DH holds a Value grade of A, while PRVA has a Value grade of C, reflecting DH's superior valuation metrics and earnings outlook [7].

PRIVI 1 3 rd Quarter 2024 Results November 7, 2024 Parth Mehrotra – Chief Executive Officer David Mountcastle – Chief Financial Officer Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to: 2024 financial guidance and other projections and forecasts. These forward-looking statements invo ...

Core Insights - Privia Health reported revenue of $437.92 million for the quarter ended September 2024, reflecting a 5% increase year-over-year and a surprise of +5.67% over the Zacks Consensus Estimate of $414.44 million [1] - The company's EPS was $0.03, down from $0.05 in the same quarter last year, resulting in an EPS surprise of -50.00% compared to the consensus estimate of $0.06 [1] Financial Performance Metrics - Practice Collections reached $739.90 million, exceeding the average estimate of $716.69 million from eight analysts [3] - Care Margin was reported at $101.40 million, slightly above the average estimate of $99.80 million based on seven analysts [3] - Platform Contribution amounted to $50.30 million, surpassing the average estimate of $47.22 million from seven analysts [3] - Implemented Providers totaled 4,642, compared to the average estimate of 4,607 from three analysts [3] - Attributed Lives stood at 1.25 million, exceeding the average estimate of 1.18 million from three analysts [3] Stock Performance - Privia Health's shares have returned +25.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +3.2% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [4]